Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00119236 · ClinicalTrials.gov registry record · Phase 1
17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT00119236: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00119236 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 48 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00119236, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects and best dose of 17-AAG and irinotecan in treating patients with locally advanced or metastatic solid tumors. Drugs used in chemotherapy, such as 17-AAG and irinotecan, work in different ways to stop the growth of tumor cells either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.
Interventions
- DRUG irinotecan hydrochloride
- DRUG tanespimycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2005-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00119236
The ClinicalTrials.gov registry entry for NCT00119236 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which irinotecan hydrochloride is the first listed.
NCT00119236 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00119236 about?
NCT00119236 is a clinical study titled "17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors". This phase I trial is studying the side effects and best dose of 17-AAG and irinotecan in treating patients with locally advanced or metastatic solid tumors. Drugs used in chemotherapy, such as 17-AAG and irinotecan, work in different ways to stop the growth of tumor cells either by killing the cell...
What is the current status of trial NCT00119236?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2005-05.
What interventions are being tested in trial NCT00119236?
The interventions under investigation include: irinotecan hydrochloride (DRUG), tanespimycin (DRUG).
Who is sponsoring clinical trial NCT00119236?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.